Ranibizumab Combined With Low-Dose Sorafenib for Exudative Age-Related Macular Degeneration

Diago, Teresa; Pulido, Jose S.; Molina, Julian R.; Collet, Lucienne C.; Link, Thomas P.; Ryan, Jr., Edwin H.
February 2008
Mayo Clinic Proceedings;Feb2008, Vol. 83 Issue 2, p231
Academic Journal
Angiogenesis Is a common factor in the pathogenesis of cancer and In exudative age-related macular degeneration (AMD). Therefore, angiogenesis inhibition has been developed as a therapeutic strategy. We report 2 cases of recurrent exudative AMD in which oral sorafenib, a tyrosine kinase Inhibitor approved for cancer, was added to intravitreal ranibizumab, an antibody to vascular endothelial growth factor. These 2 patients were followed up by determination of visual acuity, fluorescein angiography, fundoscopy, and optical coherence tomography. The visual acuity of I patient Improved from 20/70 to 20/60 while he was receiving sorafenib therapy; that of the other did not. Marked improvement was noted in both patients on optical coherence tomography. Additionally, both patients appeared to receive some benefit when low-dose oral sorafenib was used as monotherapy after Its initial addition to ranibizumab therapy. Randomized trials of adding sorafenib to standard therapy for patients with neo-vascular AMD should be considered.


Related Articles

  • Ocular neovascularization. Campochiaro, Peter // Journal of Molecular Medicine;Mar2013, Vol. 91 Issue 3, p311 

    Retinal and choroidal vascular diseases constitute the most common causes of moderate and severe vision loss in developed countries. They can be divided into retinal vascular diseases, in which there is leakage and/or neovascularization (NV) from retinal vessels, and subretinal NV, in which new...

  • Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye. Hahn, Paul // Clinical Ophthalmology;2014, Vol. 8, p2129 

    Intravitreal anti-vascular endothelial growth factor (VEGF) pharmacotherapy in vitrectomized eyes remains a challenge due to the reduced half-life of these agents. Aflibercept may have stronger binding activity and a longer intravitreal half-life compared to bevacizumab and ranibizumab, but its...

  • The efficacy of ranibizumab treatment in clinical practice in patients with the wet form of age-related macular degeneration. The results of the Czech National Registry. Chrapek, Oldrich; Jarkovsky, Jiri; Studnicka, Jan; Sin, Martin; Kolar, Petr; Jirkova, Barbora; Dusek, Ladislav; Pitrova, Sarka; Rehak, Jiri // Biomedical Papers of the Medical Faculty of Palacky University i;Sep2015, Vol. 159 Issue 3, p407 

    Aims. The aim of this communication was to evaluate ranibizumab in the treatment of wet age-related macular degeneration. Methods. Anonymised data on treatment efficacy and safety were consecutively entered into the Czech national database. From 01/09/2008 to 25/10/2011, 671 patients/685 eyes...

  • VEGF-Production by CCR2-Dependent Macrophages Contributes to Laser-Induced Choroidal Neovascularization. Krause, Torsten A.; Alex, Anne F.; Engel, Daniel R.; Kurts, Christian; Eter, Nicole // PLoS ONE;Apr2014, Vol. 9 Issue 4, p1 

    Age-related macular degeneration (AMD) is the most prevalent cause of blindness in the elderly, and its exsudative subtype critically depends on local production of vascular endothelial growth factor A (VEGF). Mononuclear phagocytes, such as macrophages and microglia cells, can produce VEGF....

  • Anti-PDGF/anti-VEGF benefits wet AMD. D'Amico, Donald J.; Dugel, Pravin U.; Krader, Cheryl Guttman // Ophthalmology Times;7/1/2012, Vol. 37 Issue 13, p1 

    The article discusses the results of a phase IIb clinical trial treatment for neovascular age-related macular degeneration (AMD) in patients having visual acuity. It is found that patients receiving combination therapy, including Fovista, an investigational aptamer directed against...

  • Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes. Tatar, Olcay; Shinoda, Kei; Adam, Annemarie; Eckert, Tillmann; Eckardt, Claus; Lucke, Klaus; Deuter, Christoph; Bath-Schmidt, Karl Ulrich; Grisanti, Salvatore // British Journal of Ophthalmology;Feb2007, Vol. 91 Issue 2, p166 

    Aim: To evaluate the effect of verteporfin photodynamic therapy (PDT) on endostatin with regard to expression of vascular endothelial growth factor (VEGF) in human choroidal neovascular membranes (CNVs) secondary to age-related macular degeneration. Methods: A retrospective review of an...

  • Intravitreal Bevacizumab for Choroidal Neovascularization and Cystoid Macular Edema: A Cost-Effective Treatment? Reichel, Elias // Ophthalmic Surgery, Lasers & Imaging;Jul/Aug2005, Vol. 36 Issue 4, p270 

    Discusses the use of intravitreal bevacizumab for choroidal neovascularization and cystoid macular edema. Treatments that inhibit the bioactivity of vascular endothelial growth factor; Evidence of the effectiveness of bevacizumab for treating aged-related macular degeneration.

  • VEGF inhibition: insights from preclinical and clinical studies. Crawford, Yongping; Ferrara, Napoleone // Cell & Tissue Research;Dec2008, Vol. 335 Issue 1, p261 

    Angiogenesis, the growth of new blood vessels, is required for a variety of normal proliferative processes. Furthermore, angiogenesis is well established as also playing an important role in neoplastic growth and metastasis. Numerous regulators of angiogenesis have been identified and...

  • LUCENTIS VS AVASTIN: NEEDS MUST OR DEVIL DRIVES?  // Bandolier;May2007, Vol. 14 Issue 5, p5 

    The article compares Lucentis with Avastin, two sources of anti-vascular endothelial growth factor (VEGF) monoclonal antibodies. It notes that new monoclonal antibodies against VEGF have been shown to reduce choroidal neovascularisation of age-related macular degeneration because VEGF helps...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics